Skip to main content
Log in

Use of delafloxacin in asthma/COPD patients minimises budget impact

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2019 US dollars

Reference

  • Lodise TP, et al. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model. Clinical Drug Investigation : 10 Jul 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00938-y

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Use of delafloxacin in asthma/COPD patients minimises budget impact. PharmacoEcon Outcomes News 858, 33 (2020). https://doi.org/10.1007/s40274-020-7006-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7006-z

Navigation